Kezar Life Sciences ( (KZR) ) has shared an update.
On March 27, 2025, Kezar Life Sciences announced the appointment of Pichi (Pattie) Chiang as the principal accounting officer, effective April 1, 2025. This change is part of the company’s internal restructuring, with Marc Belsky continuing as the Chief Financial Officer. Ms. Chiang, who has been with Kezar since 2018, brings extensive experience from her previous roles in finance leadership at Achaogen and other companies in the life sciences and high-tech sectors. Her appointment is not accompanied by any new compensatory arrangements, and there are no familial or transactional conflicts of interest associated with her new role.
More about Kezar Life Sciences
Kezar Life Sciences, Inc. operates in the biopharmaceutical industry, focusing on developing novel therapies for autoimmune diseases and cancer.
YTD Price Performance: -25.72%
Average Trading Volume: 31,068
Technical Sentiment Signal: Buy
Current Market Cap: $35.65M
For a thorough assessment of KZR stock, go to TipRanks’ Stock Analysis page.